Enanta Pharmaceuticals, Inc.
ENTA · Price history
Price at last available close
$12.18
−$0.44 (-3.49%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Enanta Pharmaceuticals, Inc.
Primary reporting period: 2025-09-30 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories.
How they make money
Enanta Pharmaceuticals is a biotechnology company that generates revenue primarily through royalty payments from AbbVie for the sale of HCV products containing glecaprevir. The company also invests in the research and development of small molecule drugs for virology and immunology, aiming to out-license or collaborate on these candidates to generate future license and milestone revenues.
Products & services
The company's primary commercial product is the HCV protease inhibitor glecaprevir, which is a component of AbbVie's MAVYRET/MAVIRET regimen. Its pipeline includes clinical-stage candidates for respiratory syncytial virus (RSV) and immunology indications.
Brands & revenue mix
AbbVie's HCV regimen containing glecaprevir, which generates the royalty revenue for Enanta.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-09-30Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical companies (via licensing and collaboration agreements)Source
Disclosed major customers
- AbbVie Inc.Source
Customer concentration
The company's revenue is highly concentrated, as it is derived entirely from royalty payments under its collaboration agreement with AbbVie for the MAVYRET/MAVIRET regimen as of the fiscal year ended September 30, 2025.
Suppliers, materials & equipment
- Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturers for the production of active pharmaceutical ingredients and drug products for clinical trials; specific supplier names are not disclosed.Source
Business relationships & partnerships
Competitors
Strengths
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly revenue fell 21.6% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Diluted weighted-average shares increased 36.4% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
13
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
11
Poor
Financial Strength
22
Business Quality / Moat
0
Management
0
Growth Quality
18
Risk / Durability
21
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
27
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
35/100
Building Historical Record
Model Score 35/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for ENTA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving ENTA's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can ENTA fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does ENTA's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for ENTA to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ENTA's current valuation?
Essential Investment Snapshot
Wall Street Score
13
Opportunity Score
27
Market Cap
$354.7M
P/E Ratio
-5.5
EPS
$-2.41
52-Week High
$17.15
52-Week Low
$10.09
Beta
0.94
Analyst Target
$20.00
Shares Outstanding
21.3M
Total Revenue
$65.3M
Total Debt
$55.7M
Dividend
No current dividend
Liquidation Value / Share
$4.74
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ENTA
Detected from reported data — verify before acting.Elevated debt risk
Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on ENTA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Established royalty revenue stream from AbbVie's HCV products.
- +Strong cash and marketable securities position to fund R&D.
Potential downside factors
- −Debt risk (elevated): Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
- −Dependence on AbbVie's commercial success and market share for HCV products.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
13
Sep 21, 2026
Change
-0.1
points
Current Score
13
Oct 1, 2026
Category Changes
ENTA decreased 0.1 points because some fundamentals weakened.
Projected Score
Projected Score
10
Projected Change
-2.3 points
Preliminary comparable-period financial changes suggest decline of approximately 2.3 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$12.18
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3M | $65.3M | $67.6M | $79.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1.2M | $4.6M | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $64.0M | $60.7M | $67.6M | $79.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $86.2M | $106.7M | $131.5M | $163.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $37.7M | $43.9M | $57.9M | $52.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $122.8M | $146.1M | $189.3M | $216.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$46.5M | -$70.8M | -$104.5M | -$123.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$58.7M | -$85.3M | -$121.7M | -$137.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $12.9M | $7.7M | $10.9M | $5.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$63.1M | -$83.5M | -$117.8M | -$131.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $99K | -$1.7M | -$1.7M | $2.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$63.2M | -$81.9M | -$116.0M | -$133.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-2.41 | $-3.84 | $-5.48 | $-6.38 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 29.09M | 21.34M | 21.16M | 20.97M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 29.09M | 21.34M | 21.16M | 20.97M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$14.4M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.67
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-73.1%
Cash Change
-25.4%
Margin Change
-36.1 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included debt levels. Pressure indicators included revenue growth, EPS growth, cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 21.6%. EPS declined 22.1%. Cash declined 25.4%. Total debt declined 73.1%. Net income margin declined by 36.1 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH)
Bank of America Corp DE Reduces Stake in Enanta Pharmaceuticals, Inc. $ENTA
Enanta Pharmaceuticals to Participate in September Investor Conferences
Enanta Pharmaceuticals to Participate in September Investor Conferences
Rumor Mill · ENTA
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial